Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post $88.65 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for AngioDynamics’ earnings, with estimates ranging from $88.50 million to $88.80 million. AngioDynamics reported sales of $83.85 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.7%. The company is scheduled to announce its next earnings report on Thursday, April 4th.
On average, analysts expect that AngioDynamics will report full-year sales of $359.10 million for the current year. For the next financial year, analysts anticipate that the business will post sales of $368.42 million, with estimates ranging from $367.90 million to $368.94 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Friday, January 4th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.01. The firm had revenue of $91.50 million for the quarter, compared to analyst estimates of $89.24 million. AngioDynamics had a return on equity of 5.85% and a net margin of 5.10%. AngioDynamics’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.16 earnings per share.
Institutional investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB boosted its position in AngioDynamics by 27.8% in the 3rd quarter. Nordea Investment Management AB now owns 208,523 shares of the medical instruments supplier’s stock worth $4,533,000 after purchasing an additional 45,410 shares in the last quarter. AQR Capital Management LLC boosted its position in AngioDynamics by 41.6% in the 3rd quarter. AQR Capital Management LLC now owns 101,943 shares of the medical instruments supplier’s stock worth $2,216,000 after purchasing an additional 29,953 shares in the last quarter. Wells Fargo & Company MN boosted its position in AngioDynamics by 2.0% in the 3rd quarter. Wells Fargo & Company MN now owns 1,103,646 shares of the medical instruments supplier’s stock worth $23,993,000 after purchasing an additional 21,218 shares in the last quarter. Vanguard Group Inc boosted its position in AngioDynamics by 2.0% in the 3rd quarter. Vanguard Group Inc now owns 2,144,291 shares of the medical instruments supplier’s stock worth $46,617,000 after purchasing an additional 42,134 shares in the last quarter. Finally, Boston Advisors LLC boosted its position in AngioDynamics by 11.6% in the 4th quarter. Boston Advisors LLC now owns 49,885 shares of the medical instruments supplier’s stock worth $1,004,000 after purchasing an additional 5,200 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.
NASDAQ ANGO traded up $0.31 during trading hours on Tuesday, reaching $23.46. The stock had a trading volume of 112,658 shares, compared to its average volume of 176,330. The firm has a market cap of $871.23 million, a P/E ratio of 31.70 and a beta of 0.69. AngioDynamics has a 52-week low of $15.26 and a 52-week high of $24.49. The company has a quick ratio of 1.86, a current ratio of 2.88 and a debt-to-equity ratio of 0.25.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.